HimanshuNagarMDMS

[Pronunciation: Himanshu Nagar]

Radiation Oncology • New York, NY

Urologic Cancer

Director of Genitourinary Program at Memorial Sloan Kettering, Department of Radiation Oncology

Join to view full profile

Dr. Nagar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nagar's full profile

Already have an account?

Office
530 East 74th Street
New York, NY 10021

Summary

Dr. Himanshu Nagar is a board certified radiation oncologist who specializes in caring for patients with genitourinary malignancies.

Dr. Nagar received his undergraduate degree from Johns Hopkins University, his medical degree from the University of Texas Health Science Center at Houston and completed his residency at NewYork-Presbyterian Hospital/Weill Cornell Medicine where he served as the Chief Resident in his final year. Dr. Nagar is the recipient of numerous honors, including the Physician of the Year Award from NewYork-Presbyterian Hospital along with multiple research grants, scholarships and awards.
Dr. Nagar is actively involved in both translational and clinical research. Dr. Nagar is focused on better defining and tailoring the role of radiation therapy for prostate, bladder, and kidney cancers.

Multidisciplinary Care for Patients with Prostate Cancer

Prostate cancer is a common cancer in men. Discover how a diverse team of experts collaborates to enhance prostate cancer care, from precise diagnosis to tailor

Clinical Expertise

Prostate cancer, Kidney cancer, Bladder cancer

Education & Training

Cornell UniversityMS, Clinical and Translational Investigation, 2019 - 2024
New York-Presbyterian Hospital (Cornell Campus)Chief Residency, Radiation Oncology, 2014 - 2015
New York-Presbyterian Hospital (Cornell Campus)Residency, Radiation Oncology, 2011 - 2014
New York Presbyterian HospitalInternship, Transitional Year, 2010 - 2011
McGovern Medical School at UTHealthClass of 2010
Johns Hopkins UniversityB.A., Dual Degrees (Biology/Economics), 1995 - 1999

Work Experience

Memorial Sloan Kettering Cancer Center (New York, NY)Director Of Genitourinary Program, Department Of Radiation Oncology · July 2024 - Current
NewYork-Presbyterian Brooklyn Methodist Hospital (Brooklyn, NY)Assistant Professor · October 2022 - Current
New York-Presbyterian Hospital (New York, NY)Assistant Professor · August 2015 - Current
Weill Cornell MedicineAssistant Professor · August 2015 - Current
University of Texas M.D. Anderson Cancer Center (Houston, TX)Research Fellow · January 2007 - January 2010
Baylor College of MedicineResearch Fellow · January 2002 - January 2006
Johns Hopkins Hospital (Baltimore, MD)Research Fellow · January 1997 - January 1998

Certifications & Licensure

FL State Medical License 2022 - Present
NY State Medical License 2014 - 2027
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

Excellence in Research Award New York Presbyterian Hospital/Weill Cornell Medical College, 2012
Physician of the Year New York Presbyterian Hospital/Weill Cornell Medical College, 2013
Educational Grant American Brachytherapy Society, 2014
Lynn Sage Scholar Award Lynn Sage Cancer Research Foundation, 2014
Roentgen Resident Research Award Radiological Society of North America, 2014
Distinguished Housestaff Award New York Weill Cornell Medical Center Alumni Council, 2014
Resident of the Year New York-Presbyterian Hospital/Weill Cornell Medical College, 2015
Join now to see all

Clinical Trials

PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT) Start of enrollment: 2018 Oct 24
Active, not recruiting
Phase 1
Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks Start of enrollment: 2020 Sep 24
Active, not recruiting
Phase 2
Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer Start of enrollment: 2022 Feb 11
Recruiting
Phase 2
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Start of enrollment: 2020 Dec 15
Recruiting
Phase 3
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer Start of enrollment: 2020 Nov 06
Recruiting
Phase 1, Phase 2
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr Start of enrollment: 2024 Feb 26
Recruiting
Not Applicable
Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE) Start of enrollment: 2022 May 26
Recruiting
Not Applicable
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) Start of enrollment: 2018 Mar 28
Completed
Phase 2
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer Start of enrollment: 2017 Jul 28
Active, not recruiting
Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Start of enrollment: 2018 Sep 24
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Point: Rectal Spacer Use is Recommended for All Prostate Cancer Radiation Therapy Fractionation Regimens.
Neil B Desai, Himanshu Nagar
International Journal of Radiation Oncology, Biology, Physics. 2024-09-01
Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer.
Marshall A Diven, Lhaden Tshering, Xiaoyue Ma, Jim C Hu, Christopher Barbieri
JAMA Network Open. 2024-08-01
Corrigendum to "The role of AI in prostate MRI quality and interpretation: Opportunities and challenges" [Eur. J. Radiol. 165 (2023) 110887].
Heejong Kim, Shin Won Kang, Jae-Hun Kim, Himanshu Nagar, Mert Sabuncu
European Journal of Radiology. 2024-08-01

Press Mentions

Doubling of Radical Surgery Rates for High-Risk Prostate Cancer ReportedSeptember 9th, 2020
ASTRO to Feature ViewRay's MRIdianSeptember 10th, 2019

Grant Support

ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancerNational Cancer Institute2024–Present

Research History

Research FellowMD Anderson Cancer Center - Department of Radiation Oncology2007 - 2010
Research FellowBaylor College of Medicine - Department of Cardiology2002 - 2006
Research FellowJohns Hopkins Hospital - Department of Immunology1997 - 1998
Research FellowJohns Hopkins Hospital - Department of Neonatology1996 - 1997